CLAIMS

1. An indazolamide of formula I:



(I)

wherein

X is an NHC(O) or C(O)NH group,

R1 is a hydrogen or halogen atom, or an aminocarbonyl, acetylamino, sulphonylmethyl, aminosulphonylmethyl, linear or branched C_{1-3} alkyl or C_{1-3} alkoxy group,

R2 is a hydrogen atom or a linear or branched C_{1-6} alkyl group or an aryl(C_{1-3})alkyl group in which the abovementioned groups are optionally substituted with one or more substituents chosen from the group comprising halogen atoms, C_{1-3} alkyl and C_{1-3} alkoxy,

R3 and R4, which may be identical or different, are a hydrogen or halogen atom, or an amino, nitro, hydroxyl, linear or branched C_{1-3} alkyl, C_{1-3} alkoxy, di(C_{1-3})alkylamino, acetylamino or O-(C_{1-3})alkylphenyl group, or R3 and R4, together, form a 5- to 7-membered ring in which one or two of the said members may be a hetero atom chosen from N, S and O,

R5, R6, R7 and R8, which may be identical or different, are H or methyl;

and acid-addition salts thereof with pharmaceutically acceptable organic and mineral acids.

2. An indazolamide according to Claim 1, characterized in that R1 is H, methyl or methoxy.

3. An indazolamide according to Claim 1 or 2, characterized in that R2 is H, methyl or isopropyl.
4. An indazolamide according to any one of Claims 1 to 3, characterized in that R3 is H, methyl, hydroxyl, amino or dimethylamino.
5. An indazolamide according to any one of Claims 1 to 4, characterized in that R4 is H, methyl or hydroxyl.
6. An indazolamide according to any one of Claims 1 to 5, characterized in that R5, R6, R7 and R8 are H.
7. An indazolamide according to any one of Claims 1 to 6, characterized in that it is a salt of addition of a pharmaceutically acceptable acid chosen from the group comprising oxalic acid, maleic acid, succinic acid, citric acid, tartaric acid, lactic acid, methanesulphonic acid, para-toluenesulphonic acid, hydrochloric acid, phosphoric acid and sulphuric acid.
8. N3-((1-(2-Oxo-2-(phenylamino)ethyl)-4-piperidyl)methyl)-1-(1-methylethyl)-1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.
9. Hydrochloride salt of the compound of the preceding Claim 8.
10. N3-((1-(2-Oxo-2-(phenylamino)ethyl)-4-piperidyl)methyl)-1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.
11. Tosylate salt of the compound of the preceding Claim 10.
12. N3-((1-(2-Oxo-2-(phenylamino)ethyl)-4-piperidyl)methyl)-1-benzyl-1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.
13. Hydrochloride salt of the compound of the preceding Claim 12.
14. N3-((1-(2-Oxo-2-((4-((phenylmethyl)oxy)phenyl)amino)ethyl)-4-piperidyl)methyl)-1-(1-methylethyl)-1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.

15. N3-((1-(2-((4-Hydroxyphenyl)amino)-2-oxoethyl)-4-piperidyl)methyl)-1-(1-methylethyl)-1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.
16. Hydrochloride salt of the compound of the preceding Claim 15.
17. N3-((1-(2-Oxo-2-((4-nitrophenyl)amino)ethyl)-4-piperidyl)methyl)-1-(1-methylethyl)-1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.
18. N3-((1-(2-Oxo-2-((4-aminophenyl)amino)ethyl)-4-piperidyl)methyl)-1-(1-methylethyl)-1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.
19. Dihydrochloride salt of the compound of the preceding Claim 18.
20. 5-Methyl-N3-((1-(2-oxo-2-(phenylamino)ethyl)-4-piperidyl)methyl)-1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.
21. Hydrochloride salt of the compound of the preceding Claim 20.
22. 5-Methyl-N3-((1-(2-oxo-2-(phenylamino)ethyl)-4-piperidyl)methyl)-1-(1-methylethyl)-1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.
23. Hydrochloride salt of the compound of the preceding Claim 22.
24. N3-((1-(2-Oxo-2-((4-(dimethylamino)phenyl)amino)ethyl)-4-piperidyl)methyl)-1-(1-methylethyl)-1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.
25. Dihydrochloride salt of the compound of the preceding Claim 24.
26. N3-((1-(2-Oxo-2-((2,6-dimethylphenyl)amino)ethyl)-4-piperidyl)methyl)-1-(1-methylethyl)-1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.
27. Oxalate salt of the compound of the preceding Claim 26.
28. A process for preparing an indazolamide of formula I:



(I)

wherein

X is an NHC(O) or C(O)NH group,

R1 is a hydrogen or halogen atom, or an aminocarbonyl, acetylamino, sulphonylmethyl, aminosulphonylmethyl, linear or branched C_{1-3} alkyl or C_{1-3} alkoxy group,

R2 is a hydrogen atom or a linear or branched C_{1-6} alkyl group or an aryl(C_{1-3})alkyl group in which the abovementioned groups are optionally substituted with one or more substituents chosen from the group comprising halogen atoms, C_{1-3} alkyl and C_{1-3} alkoxy,

R3 and R4, which may be identical or different, are a hydrogen or halogen atom, or an amino, nitro, hydroxyl, linear or branched C_{1-3} alkyl, C_{1-3} alkoxy, di(C_{1-3})alkylamino, acetylamino or O-(C_{1-3})alkylphenyl group, or R3 and R4, together, form a 5- to 7-membered ring in which one or two of the said members may be a hetero atom chosen from N, S and O,

R5, R6, R7 and R8, which may be identical or different, are H or methyl;

and acid-addition salts thereof with pharmaceutically acceptable organic and mineral acids,

characterized in that it comprises the following stages:

a) condensing an amine of formula (II)



(II)

in which

X, R3, R4, R5, R6, R7 and R8 have the meanings given above,

with an indazolecarboxylic acid derivative of formula (IIIa)



(IIIa)

in which

R1 and R2 have the meanings given above, and

Y is a chlorine or bromine atom, or a group OR or OC(O)R, in which R is an alkyl with a linear or branched chain containing from 1 to 6 carbon atoms,

or of formula (IIIb)



(IIIb)

in which

R1 has the meanings given above,

to give the indazolamide of formula (I), and

b) optionally, forming an acid-addition salt of the indazolamide of formula (I) with a pharmaceutically acceptable organic or mineral acid.

29. A process according to Claim 28, characterized in that stage (a) is performed by reacting a compound of formula (II) with a compound of formula (IIIa) in which Y is chlorine or with a compound of formula (IIIb) in the presence of a suitable diluent at a temperature in the range between 0 and 140°C for a time of between 0.5 and 20 hours.

30. A process according to Claim 29, characterized in that the reaction temperature is in the range between 15 and 40°C.

31. A process according to Claim 29, characterized in that the reaction time ranges from 1 to 14 hours.

32. A process according to any one of Claims 28 to 31, characterized in that the diluent is aprotic.

33. A process according to Claim 32, characterized in that the diluent is an aprotic apolar diluent.

34. A process according to any one of Claims 28 to 33, characterized in that when Y is chlorine or bromine, the abovementioned stage a) is performed in the presence of an organic or mineral acid acceptor.

35. A pharmaceutical composition containing an effective amount of a compound of formula (I):



(I)

wherein

X is an NHC(O) or C(O)NH group,

R1 is a hydrogen or halogen atom, or an aminocarbonyl, acetylamino, sulphonylmethyl, aminosulphonylmethyl, linear or branched C_{1-3} alkyl or C_{1-3} alkoxy group,

R2 is a hydrogen atom or a linear or branched C_{1-6} alkyl group or an aryl(C_{1-3})alkyl group in which the abovementioned groups are optionally substituted with one or more substituents chosen from the group comprising halogen atoms, C_{1-3} alkyl and C_{1-3} alkoxy,

R3 and R4, which may be identical or different, are a hydrogen or halogen atom, or an amino, nitro, hydroxyl, linear or branched C_{1-3} alkyl, C_{1-3} alkoxy, di(C_{1-3})alkylamino, acetylamino or O-(C_{1-3})alkylphenyl group, or R3 and R4, together, form a 5- to 7-membered ring in which one or two of the said members may be a hetero atom chosen from N, S and O,

R5, R6, R7 and R8, which may be identical or different, are H or methyl;

or of an acid-addition salt thereof with a pharmaceutically acceptable acid, and

at least one pharmaceutically acceptable inert ingredient.

36. An intermediate of formula (II)



(II)

wherein

X is an NHC(O) or C(O)NH group,

R3 and R4, which may be identical or different, are a hydrogen or halogen atom, or an amino, nitro, hydroxyl, linear or branched C_{1-3}

alkyl, C_{1-3} alkoxy, di(C_{1-3})alkylamino, acetylamino or O-(C_{1-3})alkylphenyl group, or R3 and R4, together, form a 5- to 7-membered ring in which one or two of the said members may be a hetero atom chosen from N, S and O,

R5, R6, R7 and R8, which may be identical or different, are H or methyl.

37. An amine according to Claim 35, characterized in that R3 is H, methyl, hydroxyl, benzyloxy, nitro, amino or dimethylamino.

38. An amine according to Claim 35, characterized in that R4 is H or methyl.

39. An amine according to Claim 35, characterized in that R5, R6, R7 and R8 are H.